Print

FDA approves new targeted therapy for advanced pancreatic cancer

https://www.facingourrisk.org/XRAY/bizengri-for-NRG1-pancreatic-cancer
Full article: https://pmc.ncbi.nlm.nih.gov/articles/PMC11878197/

A new treatment called Bizengri has been approved by the FDA for patients with advanced or metastatic pancreatic cancer. This treatment targets pancreatic cancer or non-small cell lung cancers that have a rare tumor mutation called an NRG1 fusion. (Posted 7/24/25)

Questions To Ask Your Health Care Provider

Open Clinical Trials

The following treatment studies are enrolling people diagnosed with pancreatic cancer.

Other clinical trials for people with pancreatic cancer can be found here.


About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.